Monday, August 25, 2014

The Plastic Brain

Read this quote about how Merzenich thinks about his brain's decline.


"I want to put my brain to the best possible use as long as it is possible."

"Science tells us that a key to sustaining and growing our neurological abilities is seriousness of purpose.  I am old enough to have retired, but shall not withdraw to a life of comfort and ease because I know that the brain slowly dies when nothing that it does matters to it. ... understand that what sustains your brain sustains you.  You need to continue to work at things that support your brain's health now, and continue to work in ways that support it out to the end of your time on Earth."

- Dr. Michael Merzenich 
 


Brain Plasticity sites:
 

 





Tuesday, August 5, 2014

Neon in Vancouver

Neon used to rule the night in Vancouver, especially on the famous Granville Street entertainment strip. At one time the city was second only to Shanghai for the most neon signs.

Monday, August 4, 2014

Yoga Pose near Taj Mahall


 · 
"Breathe and everything changes." ~Seane Corn in this week's show, Yoga, Meditation in Action:

Triple Arthrodesis post operative X-Ray








Dr. Lam Foot / Ankle Straight Talk: October 2012



www.drkevinlam.com
1600 × 554Search by image
Case #2: Post operative Triple Arthrodesis 3 years later without pain in the ankle or foot.

Source:    http://www.drkevinlam.com/2012_10_01_archive.html





Triple Arthrodesis

This is a procedure I have undergone:


Triple Arthrodesis

​What is triple arthrodesis?

Triple arthodesis is used to address many types of foot deformity and pain. This procedure fuses three joints in the back of

The talonavicular (blue arrow), subtalar (red arrow) and calcaneocuboid (green arrow) joints 
the foot. These joints, shown in the image to the right, are the talonavicular (blue arrow), subtalar (red arrow) and calcaneocuboid (green arrow).

What are the goals of triple arthrodesis?

Surgeons try to avoid fusions, but sometimes pain and deformity are so severe that this procedure offers the best chance of producing a less painful foot with better alignment. Fusions often improve stability and allow for easier standing and walking. The triple arthrodesis is a time-tested, durable procedure.

What signs indicate surgery may be needed?

Triple arthrodesis is indicated for severe arthritis, instability or deformity that cannot be controlled with nonsurgical approaches. Other conditions, such as severe flatfoot, abnormal connections between bones, excessively high arches and joint instability due to neuromuscular disease, can also warrant treatment with fusion.

When should I avoid surgery?

Patients who are still growing are not ideal candidates as they may develop additional deformity as they grow. Patients who use tobacco, have an active infection or have poor healing potential are at higher risk for complications. Nonsurgical measures such as bracing and anti-inflammatories should be attempted first. If another surgical procedure that leaves the joint intact can achieve the same goal, this is preferred over a fusion.

General Details of Procedure

Two incisions are generally required for this procedure. The traditional method involves one incision on each side of the foot.


Typical incision sites for a triple arthrodesis
Within each joint cartilage is removed, bony surfaces roughened, and defects filled. Once all three joints have been prepared, they are put into place and hardware is placed to stabilize the reconstruction and promote healthy fusion.

Specific Technique

The surgeon confirms proper position of the bones with an X-ray while in the operating room. Then all incisions are closed and covered with bulky dry sterile dressings. To lessen post-operative pain, the nerves around the knee or ankle may be numbed with medication.

What happens after surgery?

The rate of healing is variable and is influenced by many factors. In general, the foot is kept elevated with no weight on it for the first two weeks to minimize swelling and allow healing of the skin. Stitches may be removed two to three weeks after surgery.
Different weight bearing protocols may be used. After signs of healing are noted, progressive weight bearing is allowed until full weight bearing is reached. This typically takes three months. A removable boot may be used rather than a cast.

Potential Complications

Successful triple arthrodesis is appreciated by patients. Most feel that the loss of motion is a very acceptable trade-off for pain reduction. In the first two to three weeks, the most likely complication is wound breakdown and/or infection. These are best avoided by not smoking, elevating the foot, avoiding any weight on the foot, and keeping the surgical dressing clean and dry.
There are complications that relate to surgery in general. These include the risks associated with anesthesia, infection, damage to nerves and blood vessels, and bleeding or blood clots.
The most common long-term consequence of triple arthrodesis is gradual development of arthritis in other joints of the foot and ankle. These changes can take years or even decades to develop and many never become noticeable to the patient. 

Frequently Asked Questions

Will I have stiffness after surgery?
Yes, you can expect some degree of stiffness in your foot as a result of the surgery. You will maintain up-and-down motion, but side-to-side motion will become limited.  This will be most noticeable on uneven surfaces but is usually a good trade-off for reasonable pain relief, improved stability and/or deformity correction.
Will I be able to return to my usual activities?
You can generally expect to return to most activities in life, but the stiffness in side-to-side motion will limit sports participation. 
When can I expect to have recovered from a triple arthrodesis?
A significant amount of healing will occur in the first three months. However, it takes about one year for maximum improvement.
Are there side effects to triple arthrodesis?
As one part of the foot is made stiffer, other structures are forced to accept more stress, which increases the chances that they may wear out. This often takes many years or decades to become noticeable.

When will I be able to take a shower?
Generally, showering is allowed once all wounds have healed. This usually takes place within the first two to four weeks depending on swelling and soft-tissue health.
Will I be able to fit into regular shoes?
Typically patients fit into a shoe after surgery better than before surgery.
When will I be able to bear weight on my foot?
Partial weight bearing typically is allowed once incisions have healed. Full weight bearing generally takes between two and four months.
The American Orthopaedic Foot & Ankle Society (AOFAS) offers information on this site as an educational service. The content of FootCareMD, including text, images and graphics, is for informational purposes only. The content is not intended to substitute for professional medical advice, diagnoses or treatments. If you need medical advice, use the "Find an Orthopaedic Foot & Ankle Surgeon" tool at the top of this page or contact your primary doctor.



 Source: http://www.aofas.org/footcaremd/treatments/Pages/Triple-Arthrodesis.aspx 









Tuesday, June 3, 2014

Prostate Cancer





HEALTH
Study May Alter Approach to Prostate Cancer



By ANDREW POLLACK 
JUNE 1, 2014




A study supports chemotherapy for men early in their treatment for advanced prostate cancer.CreditGerry Broome/Associated Press


 

CHICAGO — Many men with prostate cancer put off using chemotherapy as long as possible, fearing its side effects.

But a new study has found that men given chemotherapy early in their treatment for advanced disease lived a median of nearly 14 months longer than those who did not get early chemotherapy. 

The result could upend the established treatment practice, researchers said here on Sunday.

“We haven’t seen survival benefits like that for any therapy in prostate cancer,”
said Dr. Michael J. Morris, an associate professor at the Memorial Sloan-Kettering Cancer Center, who was not involved in the study but was selected to publicly comment on it at the annual meeting of the American Society of Clinical Oncology.

Another study being presented on Sunday found that drugs called aromatase inhibitors might be better than the standard drug tamoxifen in preventing a recurrence of disease in premenopausal women with early breast cancer.

Both studies are being featured in the plenary session on Sunday, meaning they were deemed among the most noteworthy of the more than 5,000 studies being presented at the meeting. 

In a conference that typically celebrates the latest and greatest drug, all four studies chosen for the plenary session this year are about better ways of using older drugs, showing that there can be a lot to learn even after drugs get to market.

Dr. Nicholas J. Vogelzang, an author of the study on prostate cancer, said that the findings would change practice and that he had already started discussing this option with patients. The challenge, he said, is getting men to agree.

“Not many of them want to do chemotherapy, even though the numbers are convincing,” said Dr. Vogelzang, who works at the Comprehensive Cancer Centers of Nevada.

The study’s findings apply to a fairly narrow group of patients
— men whose cancer has already spread beyond the prostate gland at the time of diagnosis, or whose cancer has come back after surgery or radiation treatment and still remains susceptible to hormone therapy.

Only a small fraction of men have metastatic prostate cancer at the time of the initial diagnosis because prostate cancer screening using a blood test typically detects the disease before it has spread.

But screening is expected to become less common because a government advisory committee, the United States Preventive Services Task Force, has recommended against routine screening, saying that more men are harmed by unnecessary treatments for prostate cancer than are saved from death by screening. That could lead to an increase in men whose initial diagnosis is metastatic cancer, Dr. Vogelzang said.

The study, sponsored by the National Cancer Institute, involved 790 men who received either only hormone therapy or hormone therapy in addition to at most six infusions of docetaxel spaced three weeks apart.

Those who received the chemotherapy lived a median of 57.6 months, compared with 44.0 months in the control group, a difference of 13.6 months. The difference in survival was even greater — 17 months — for the patients whose cancer had spread more extensively. Dr. Morris of Sloan-Kettering said those men were the best candidates for early chemotherapy.

Docetaxel is sold under the brand name Taxotere by Sanofi, but generic versions are also available. It was approved for metastatic prostate cancer in 2004. In the last few years, several other drugs have been approved, like Zytiga from Johnson & Johnson and Xtandi from Medivation and Astellas Pharma.


But docetaxel and the newer drugs are typically used after hormone therapy has stopped working. In that setting, each of them has extended median survival by about two to five months in clinical trials.

Dr. Matthew R. Cooperberg, associate professor of urology at the University of California, San Francisco, said doctors were starting to use the newer agents before docetaxel, pushing chemotherapy further back in the sequence.

So the new study “is, to an extent, bucking the tide,” he said. “This trial may be evidence that the role for chemo is earlier, when patients are healthier and the disease burden is relatively low.”

The results also raise the question of whether the other prostate cancer drugs would also provide a much greater survival advantage if used earlier. Some trials are underway to determine that.

One issue is that early treatment is often handled by urologists, not oncologists. And many urologists do not administer chemotherapy.

Dr. Morris said he did not think earlier use of docetaxel would diminish sales of the newer agents. Men will eventually become resistant to hormone therapy, he said, and will need the newer agents.



 
Read More: